HomeCompareSESN vs EQR

SESN vs EQR: Dividend Comparison 2026

SESN yields 318.07% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SESN wins by $2251.77M in total portfolio value
10 years
SESN
SESN
● Live price
318.07%
Share price
$0.63
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2251.82M
Annual income
$1,391,325,451.55
Full SESN calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — SESN vs EQR

📍 SESN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSESNEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SESN + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SESN pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SESN
Annual income on $10K today (after 15% tax)
$27,035.62/yr
After 10yr DRIP, annual income (after tax)
$1,182,626,633.82/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, SESN beats the other by $1,182,621,979.55/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SESN + EQR for your $10,000?

SESN: 50%EQR: 50%
100% EQR50/50100% SESN
Portfolio after 10yr
$1125.93M
Annual income
$695,665,463.58/yr
Blended yield
61.79%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

SESN
Analyst Ratings
5
Buy
3
Hold
Consensus: Buy
Altman Z
-26.2
Piotroski
3/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SESN buys
0
EQR buys
0
No recent congressional trades found for SESN or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSESNEQR
Forward yield318.07%5.87%
Annual dividend / share$2.00$3.47
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$2251.82M$47.8K
Annual income after 10y$1,391,325,451.55$5,475.61
Total dividends collected$2167.12M$23.0K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold

Year-by-year: SESN vs EQR ($10,000, DRIP)

YearSESN PortfolioSESN Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$42,507$31,806.62$11,380$679.82+$31.1KSESN
2$171,836$126,354.35$13,014$837.25+$158.8KSESN
3$661,246$477,381.03$14,961$1,036.20+$646.3KSESN
4$2,424,371$1,716,837.53$17,297$1,289.22+$2.41MSESN
5$8,476,840$5,882,763.50$20,121$1,613.15+$8.46MSESN
6$28,293,724$19,223,504.84$23,561$2,030.84+$28.27MSESN
7$90,240,261$59,965,976.10$27,783$2,573.54+$90.21MSESN
8$275,301,033$178,743,953.65$33,013$3,284.39+$275.27MSESN
9$804,202,218$509,630,112.70$39,547$4,223.51+$804.16MSESN
10$2,251,821,824$1,391,325,451.55$47,791$5,475.61+$2251.77MSESN

SESN vs EQR: Complete Analysis 2026

SESNStock

Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer; to treat non-muscle invasive carcinoma in situ of the bladder in patients previously treated with BCG; and for the treatment of squamous cell carcinoma of the head and neck, as well as VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule-positive solid tumors. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Full SESN Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this SESN vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SESN vs SCHDSESN vs JEPISESN vs OSESN vs KOSESN vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.